Doxorubicin versus methotrexate both combined with cyclophosphamide, 5- fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer - A randomised study with more than 10 years follow-up from the Danish breast cancer cooperative group

European Journal of Cancer

Volumn 35, Issue 1, 1999, Pages 39-46

  Andersson, M ^a   Lindegaard Madsen, E ^b   Overgaard, M ^c   Rose, C ^b   Dombernowsky, P ^d   Mouridsen, H T ^a  

^a FINSEN LABORATORY   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

5 fluorouracil; Breast neoplasms; Chemo endocrine therapy; Cyclophosphamide; Doxorubicin; Methotrexate; Tamoxifen

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ADULT; ADVANCED CANCER; ARTICLE; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENMARK; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SCREENING; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; NAUSEA; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DOXORUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; METHOTREXATE; MIDDLE AGED; NEOPLASM STAGING; POSTMENOPAUSE; SURVIVAL ANALYSIS; TAMOXIFEN;

EID: 0344177500     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00354-2     Document Type: Article

References (21)

1. Greenspan E. Combination cytotoxic chemotherapy in advanced disseminated breast cancer. J Mt Sinai Hosp. 33:1972;1-27.
2. Cooper R.G. Combination chemotherapy in hormone resistant breast cancer. Proc Am Assoc Cancer Res. 10:1969;(abstract) 15.
3. Carter S.K. Integration of chemotherapy into combined modality treatment of solid tumours VII. Adenocarcinoma of the breast. Cancer Treat Rev. 3:1976;141-174.
4. Beatson G.T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet. ii:1896;162-165.
5. Mouridsen H.T., Rose C., Engelsman E., et al. Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized study of CMF vs CMF plus tamoxifen. Eur J Cancer Clin Oncol. 21:1985;291-299.
6. Brincker H., Rose C., v. d. Maase H., et al. A randomized study of CAF+TAM (tamoxifen) versus CMF+TAM in metastatic breast cancer. Proc Am Soc Clin Oncol. 3:1984;(abstract) 113.
7. Madsen EL, Andersson M, Mouridsen HT, et al. A randomized study of CAF+TAM (tamoxifen) versus CMF+TAM in disseminated breast cancer. 5th Breast Cancer Working Conference, EORTC Breast Cancer Cooperative Group, September 1991, A75, (abstract) 1991.
8. Hayward J.L., Carbone P.P., Heuson J.C., et al. Assessment of response to therapy in advanced breast cancer. Cancer. 39:1977;1289-1291.
9. World Health Organisation. WHO Handbook for reporting Results of Cancer Treatment. Geneva, WHO Offset Publication 48, 1979.
10. Cox DR. The Analysis of Binary Data. London, Methuen, 1970.
11. Cox D.R. Regression models and life tables. J Roy Stat Soc B. 34:1972;187-195.
12. Muss H.B., White D.R., Richards F., et al. Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer. Cancer. 42:1978;2141-2148.
13. Bull J.M., Tormey D.C., Li S-H., et al. A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer. 41:1978;1649-1657.
14. Smalley R.V., Lefante J., Bartolucci A., et al. A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer. Breast Cancer Res and Treat. 3:1983;209-220.
15. Tormey D.C., Weinberg V.E., Leone L.A., et al. A comparison of intermittent vs continuous and of adriamycin vs methotrexate 5-drug chemotherapy for advanced breast cancer. A Cancer and Leukemia Group B study. Am J Clin Oncol. 7:1984;231-239.
16. Cummings F.J., Gelman R., Horton J. Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors. J Clin Oncol. 3:1985;932-940.
17. Parvinen L-M., Numminen S. Chemotherapy in advanced breast carcinoma. Comparison between doxorubicin-cyclophosphamide and cyclophosphamide-methotrexate-5-fluorouracil-vincristine-prednisone. Acta Radiol Oncol. 24:1985;391-394.
18. Aisner J., Weinberg V., Perloff M., et al. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. J Clin Oncol. 5:1987;1523-1533.
19. Falkson G., Tormey D.C., Carey P., et al. Long-term survival of patients treated with combination chemotherapy for metastatic breast cancer. Eur J Cancer. 27:1991;973-977.
20. A'Hern R.P., Smith I.E., Ebbs S.R. Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. Br J Cancer. 67:1993;801-805.
21. Seidman A.D. Chemotherapy for advanced breast cancer a current perspective. Sem Oncol. 23:1996;(Suppl 2) 55-59.